Please note that only limited free access to this journal is available in your country or territory.

To access the full content of this article you must purchase it (US$9.49). After payment of this one-off fee, you will gain unrestricted online access to the article and a PDF version sent to your email.

As part of our special introductory offer, after purchasing this article you will have unrestricted access to all the articles in this issue for free!

Registered users can purchase/access the article by logging in below. To register for free click here

Registered users login here:

  • Email Address:
     
  • Password:
     
  •  
If you have forgotten your password click here
0 rating

THERAPEUTICS RESEARCH

Appel GB, Contreras G, Dooley MA et al. J Am Soc Nephrol 2009;20:1103–12.

Intravenous cyclophosphamide (IVC), the standard treatment for lupus nephritis (LN), has been associated with ovarian failure and secondary malignancies. Consequently, there has been a need for the development of alternative therapies with less toxicity but at least equal efficacy to IVC. The results of previous clinical trials suggest that mycophenolate mofetil (MMF) is equal or superior to IVC in terms of safety and induction of LN remission. Data from the present large, international trial demonstrate the overall safety and efficacy of MMF to be comparable to IVC as an induction therapy in LN.

 

Mycophenolate mofetil (MMF) is an immunosuppressive agent that inhibits lymphocyte proliferation via a blockade of the enzyme inosine 5’-monophosphate dehydrogenase (an enzyme required in order for lymphocytes to generate the necessary purines for DNA/RNA synthesis) resulting in anti-inflammatory effects.

Please login or register to continue reading this article
Return to top
Login/Register

Post Page On

LATEST ARTICLES

Our most popular articles